Navigation path

Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information

Eflornithine in combination with sulindac

EU orphan designation number: EU/3/12/1086   
Active ingredient: Eflornithine in combination with sulindac
Indication: Treatment of familial adenomatous polyposis
Sponsor: Cancer Prevention Pharma Limited
c/o Arnold & Porter (UK) LLP, Tower 42, 25 Old Broad Street, London EC2N 1HQ, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
28/01/2013 Orphan designation EMA/OD/130/12 (2013)475 of 24/01/2013